Vonafexor
EYP001-208
Phase 2 small_molecule active
Quick answer
Vonafexor for Alport Syndrome is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Alport Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active